| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Khaldoun Kerrou | |
| Jean-Noël Talbot | |||
| Sona Balogova | |||
| Valérie Nataf | |||
| Virginie Huchet | |||
| Françoise Montravers | |||
| Laure Michaud | |||
| P2860 | cites work | FDG-PET imaging in Merkel cell carcinoma - value of head-to-toe scan. | Q46911998 |
| Detection of primary and metastatic lesions by [18F]fluoro-2-deoxy-D-glucose PET in a patient with thymic carcinoid | Q46912262 | ||
| Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. | Q46925547 | ||
| Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism | Q46982092 | ||
| The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study | Q46983836 | ||
| Comparison of 18F-FDG PET/CT and 111In pentetreotide scan for detection of Merkel cell carcinoma | Q47395098 | ||
| 18F-DOPA PET/CT but not 68Ga-DOTA-TOC PET/CT revealed the underlying cause of ectopic Cushing syndrome | Q48228208 | ||
| Ectopic Cushing's syndrome caused by a well differentiated ACTH-secreting neuroendocrine carcinoma of the ileum | Q48303939 | ||
| Is there an optimal scan time for 6-[F-18]fluoro-L-DOPA PET in pheochromocytomas and paragangliomas? | Q48722245 | ||
| Impact of Ga-68 DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia. | Q51320250 | ||
| Ectopic ACTH-syndrome due to a neuroendocrine tumour of the appendix. | Q51400792 | ||
| Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study. | Q51564397 | ||
| Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. | Q51571439 | ||
| Noninvasive diagnosis of focal hyperinsulinism of infancy with [18F]-DOPA positron emission tomography. | Q52030252 | ||
| Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma. | Q53136302 | ||
| The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept | Q28237047 | ||
| 6-[F-18]fluoro-L-DOPA positron emission tomography in the imaging of Merkel cell carcinoma: preliminary report of three cases with 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography or pentetreotide-(111In) SPECT data. | Q30998485 | ||
| [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas | Q31831286 | ||
| Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors | Q31831789 | ||
| 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels | Q32002112 | ||
| Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients | Q33532372 | ||
| Utility of various functional and anatomic imaging modalities for detection of ectopic adrenocorticotropin-secreting tumors. | Q33738687 | ||
| Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma | Q35009855 | ||
| Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy | Q35198539 | ||
| Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour. | Q35201548 | ||
| (111)In-octreotide scintigraphy for identification of metastatic medullary thyroid carcinoma in children and adolescents | Q35744505 | ||
| Clinical utility of functional imaging with ¹⁸F-FDOPA in Von Hippel-Lindau syndrome | Q35869517 | ||
| Developments in PET for the detection of endocrine tumours | Q36069350 | ||
| The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast | Q36343008 | ||
| EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma | Q36467722 | ||
| The value of radiologic interventions and (18)F-DOPA PET in diagnosing and localizing focal congenital hyperinsulinism: systematic review and meta-analysis | Q36557458 | ||
| The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules | Q36705852 | ||
| Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma | Q37482780 | ||
| Medullary thyroid cancer: management guidelines of the American Thyroid Association | Q37495961 | ||
| Limited value of 18F-F-DOPA PET to localize pancreatic insulin-secreting tumors in adults with hyperinsulinemic hypoglycemia | Q37633275 | ||
| High-grade neuroendocrine carcinoma of the colon, long-term survival in advanced disease. | Q37788615 | ||
| Novel medical therapies of recurrent and metastatic gastroenteropancreatic neuroendocrine tumors. | Q37936908 | ||
| Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis | Q37987448 | ||
| Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET. | Q53149999 | ||
| Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer. | Q53163603 | ||
| ⁶⁸Ga-DOTANOC PET/CT in patients with carcinoma of unknown primary of neuroendocrine origin. | Q53176484 | ||
| The diagnostic role of 68Ga-DOTATATE PET/CT in the detection of neuroendocrine tumours. | Q53214032 | ||
| Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. | Q53218854 | ||
| Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (≥10%) well-differentiated endocrine carcinoma staging. | Q53252569 | ||
| Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. | Q53343316 | ||
| The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. | Q53463747 | ||
| Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients. | Q53503895 | ||
| Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours. | Q53511553 | ||
| PET with 18F-DOPA in the imaging of parathyroid adenoma in patients with primary hyperparathyroidism. A pilot study. | Q53516627 | ||
| Whole-body PET/CT with 11C-meta-hydroxyephedrine in tumors of the sympathetic nervous system: feasibility study and comparison with 123I-MIBG SPECT/CT. | Q53518297 | ||
| Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? | Q53521560 | ||
| The added value of [18F]fluoro-L-DOPA PET in the diagnosis of hyperinsulinism of infancy: a retrospective study involving 49 children | Q57199759 | ||
| 68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT | Q57757715 | ||
| Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization | Q57820372 | ||
| Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma | Q57998575 | ||
| Gastroenteric neuroendocrine neoplasms classification: Comparison of prognostic models | Q60609598 | ||
| Comparison of [111In]pentetreotide-SPECT and [18F]FDOPA-PET in the localization of extra-adrenal paragangliomas: the case for a patient-tailored use of nuclear imaging modalities | Q61647431 | ||
| Somatostatin analogue scintigraphy. A simple and sensitive method for the in vivo visualization of Merkel cell tumors and their metastases | Q68144737 | ||
| New solid-phase enzyme immunoassay of neuron-specific enolase in serum: effect of storage temperature, lipemia, icterus, and hemolysis | Q68534544 | ||
| In vivo demonstration of enzyme activity in endocrine pancreatic tumors: decarboxylation of carbon-11-DOPA to carbon-11-dopamine | Q70845101 | ||
| Pancreatic neuroendocrine tumors: diagnosis with PET | Q72176253 | ||
| Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy | Q73081509 | ||
| Positron emission tomography in the staging of small-cell lung cancer : a preliminary study | Q73598716 | ||
| F-18 FDG Accumulation in an Octreotide Negative Merkel Cell Tumor | Q73851605 | ||
| Evaluation of primary pulmonary carcinoid tumors using FDG PET | Q74515559 | ||
| Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? | Q74580280 | ||
| The classification of carcinoid tum ours | Q76405787 | ||
| Imaging of a metastatic gastrointestinal carcinoid by F-18-DOPA positron emission tomography | Q77956821 | ||
| Clinical added-value of 18FDG PET in neuroendocrine-merkel cell carcinoma | Q79839883 | ||
| Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma | Q80162213 | ||
| Primary hepatic carcinoid tumor presenting as Cushing's syndrome | Q80448064 | ||
| Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases | Q80775181 | ||
| Small-cell carcinoma of the prostate | Q80796566 | ||
| Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer | Q82337136 | ||
| An unusual case of ectopic ACTH syndrome | Q83082042 | ||
| Complete remission in a patient with metastatic mixed adenocarcinoma/extrapulmonary small cell carcinoma of the prostate | Q83468755 | ||
| A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans | Q83770192 | ||
| A comparison of the performance of ⁶⁸Ga-DOTATATE PET/CT and ¹²³I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma | Q83969643 | ||
| Effect of short-term proton pump inhibitor treatment and its discontinuation on chromogranin A in healthy subjects | Q84435171 | ||
| The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors | Q84978637 | ||
| Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer | Q44982573 | ||
| Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer | Q45003900 | ||
| Positron emission tomography/computed tomography diagnostics by means of fluorine-18-L-dihydroxyphenylalanine in congenital hyperinsulinism | Q45057794 | ||
| Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours | Q45126334 | ||
| In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas | Q45168715 | ||
| Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 dihydroxyphenylalanine positron emission tomography: a meta-analysis. | Q45206732 | ||
| 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine | Q45923759 | ||
| The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. | Q45940015 | ||
| 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas. | Q45941041 | ||
| F-18 FDG PET imaging of urinary bladder oat cell carcinoma with widespread osseous metastases. | Q45986536 | ||
| Combining 6-fluoro-[18F]l-dihydroxyphenylalanine and [18F]fluoro-2-deoxy-d-glucose positron emission tomography for distinction of non-carcinoid malignancies in carcinoid patients. | Q45992393 | ||
| 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid | Q46107039 | ||
| Impact of fluorodihydroxyphenylalanine-18F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors. | Q46164645 | ||
| Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours | Q46167330 | ||
| Diagnostic imaging in Merkel cell carcinoma: lessons to learn from 16 cases with correlation of sonography, CT, MRI and PET. | Q46183322 | ||
| The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors | Q46195094 | ||
| Premedication with carbidopa masks positive finding of insulinoma and beta-cell hyperplasia in [(18)F]-dihydroxy-phenyl-alanine positron emission tomography | Q46317207 | ||
| F-18-FDG-PET/CT imaging of small cell carcinoma of the colon | Q46419613 | ||
| Characterization of hyperinsulinism in infancy assessed with PET and 18F-fluoro-L-DOPA. | Q46421494 | ||
| [18F]fluoro-2-deoxy-D-glucose ([18F]FDG) positron emission tomography imaging of thymic carcinoid tumor presenting with recurrent Cushing's syndrome | Q46427931 | ||
| The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas | Q46660401 | ||
| 11C-hydroxyephedrine positron emission tomography imaging of pheochromocytoma: a single center experience over 11 years | Q46670585 | ||
| 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. | Q46674496 | ||
| Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. | Q46694597 | ||
| Thymic carcinoid tumor revealed by a Cushing's syndrome: usefulness of positron emission tomography | Q46730184 | ||
| A Pulmonary adrenocorticotropin-secreting carcinoid tumor localized by 6-Fluoro-[18F]L-dihydroxyphenylalanine positron emission/computed tomography imaging in a patient with Cushing's syndrome. | Q46868374 | ||
| ¹¹¹In-DTPA⁰-octreotide (Octreoscan), ¹³¹I-MIBG and other agents for radionuclide therapy of NETs | Q37990403 | ||
| PDX-1, CDX-2, TTF-1, and CK7: a reliable immunohistochemical panel for pancreatic neuroendocrine neoplasms | Q38002300 | ||
| The predictive value of imaging studies in evaluating regional lymph node involvement in Merkel cell carcinoma | Q38007070 | ||
| Diagnostic performance of fluorine-18-dihydroxyphenylalanine positron emission tomography in diagnosing and localizing the focal form of congenital hyperinsulinism: a meta-analysis | Q38033996 | ||
| Evaluation of the role of [18F]FDG-PET/CT and [68Ga]DOTATOC-PET/CT in differentiating typical and atypical pulmonary carcinoids | Q38898271 | ||
| Diagnosing and treating small-cell carcinomas of prostatic origin | Q39411095 | ||
| The risk of metachronous cancers in patients with small-intestinal carcinoid tumors: a US population-based study | Q39635773 | ||
| Pheochromocytomas: detection with 18F DOPA whole body PET--initial results.. | Q40663240 | ||
| [111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment | Q41011017 | ||
| Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma | Q42471133 | ||
| The role of PET-CT scan with somatostatin analogue labelled with gallium-68 (⁶⁸Ga-DOTA-TATE PET-CT) in diagnosing patients with disseminated medullary thyroid carcinoma (MTC). | Q42479418 | ||
| The predictive value of preoperative fluorine-18-L-3,4-dihydroxyphenylalanine positron emission tomography-computed tomography scans in children with congenital hyperinsulinism of infancy | Q42686424 | ||
| The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors | Q42841246 | ||
| F-18 FDG PET/CT imaging in small cell prostate cancer | Q43060984 | ||
| Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. | Q43097931 | ||
| 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine t | Q43108087 | ||
| Role of [(18)F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer | Q43119569 | ||
| The value of 11C-5-hydroxy-tryptophan positron emission tomography in neuroendocrine tumor diagnosis and management: experience from one center. | Q43120453 | ||
| Value of combined 6-[18F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours | Q43131952 | ||
| Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging | Q43184440 | ||
| The prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma | Q43233301 | ||
| A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors | Q43243195 | ||
| Clinical usefulness of fluoro-2-deoxy-D-glucose PET in a case with multiple bone metastases of carcinoid tumor after ten years | Q43250985 | ||
| Value of 18F-fluoro-L-dopa PET in the preoperative localization of focal lesions in congenital hyperinsulinism | Q43285358 | ||
| Widespread metastases in small cell carcinoma of the prostate on FDG PET/CT. | Q43289399 | ||
| Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma | Q43296875 | ||
| PET/CT using ¹⁸F-FDOPA provides improved staging of carcinoid tumor patients in a Canadian setting | Q43578612 | ||
| Functional imaging of malignant paragangliomas and carcinoid tumours | Q43611335 | ||
| 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma | Q43681931 | ||
| Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors | Q43690572 | ||
| Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma | Q43721190 | ||
| Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study | Q43794934 | ||
| Merkel cell carcinoma and iodine-131 metaiodobenzylguanidine scan | Q43827457 | ||
| 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma | Q43860790 | ||
| Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67. | Q44068733 | ||
| Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors | Q44091290 | ||
| Thymic neuroendocrine tumour (carcinoid): clinicopathological features of four patients with different presentation | Q44286238 | ||
| Localization of medullary thyroid carcinoma metastasis in a multiple endocrine neoplasia type 2A patient by 6-[18F]-fluorodopamine positron emission tomography | Q44306808 | ||
| 18F-DOPA positron emission tomography for the detection of glomus tumours | Q44347196 | ||
| Positron emission tomography with [(18)F]FDOPA and [(18)F]FDG in the imaging of small cell lung carcinoma: preliminary results. | Q44510110 | ||
| FDG PET imaging in hereditary thyroid cancer | Q44660507 | ||
| 18F-FDG PET, somatostatin receptor scintigraphy, and CT in metastatic medullary thyroid carcinoma: a clinical study and an analysis of the literature | Q44853538 | ||
| Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. | Q44964622 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 2.0 Generic | Q44128984 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 6 | |
| P921 | main subject | fludeoxyglucose (18F) | Q419849 |
| neuroendocrine tumor | Q1981276 | ||
| radiopharmaceutical | Q9178218 | ||
| thyroid neoplasm | Q13632630 | ||
| P1104 | number of pages | 24 | |
| P304 | page(s) | 943-966 | |
| P577 | publication date | 2013-02-16 | |
| 2013-06-01 | |||
| P1433 | published in | European Journal of Nuclear Medicine and Molecular Imaging | Q15708890 |
| P1476 | title | 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type | |
| P478 | volume | 40 |
| Q90163212 | (Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast Cancer |
| Q26991479 | 6-[18F]fluoro-L-DOPA: a well-established neurotracer with expanding application spectrum and strongly improved radiosyntheses |
| Q36195528 | A Pilot Comparison of 18F-fluorocholine PET/CT, Ultrasonography and 123I/99mTc-sestaMIBI Dual-Phase Dual-Isotope Scintigraphy in the Preoperative Localization of Hyperfunctioning Parathyroid Glands in Primary or Secondary Hyperparathyroidism: Influe |
| Q34562501 | A challenging case of an ectopic cushing syndrome. |
| Q90294776 | Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms |
| Q48164114 | Alcohol-Enhanced Cu-Mediated Radiofluorination. |
| Q50972560 | Automated production at the curie level of no-carrier-added 6-[(18)F]fluoro-L-dopa and 2-[(18)F]fluoro-L-tyrosine on a FASTlab synthesizer. |
| Q38674597 | Consensus on management of advanced medullary thyroid carcinoma on behalf of the Working Group of Thyroid Cancer of the Spanish Society of Endocrinology (SEEN) and the Spanish Task Force Group for Orphan and Infrequent Tumors (GETHI). |
| Q35853776 | Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion from a Meckel diverticulum neuroendocrine tumor: case report |
| Q48227522 | Diagnostic utility of PET/CT with 18F-DOPA and 18F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff |
| Q38260542 | Ileal neuroendocrine tumors and heart: not only valvular consequences |
| Q89420663 | Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies |
| Q35182968 | Mid-gut ACTH-secreting neuroendocrine tumor unmasked with (18)F-dihydroxyphenylalanine-positron emission tomography. |
| Q39016753 | Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management |
| Q38169928 | Neuroendocrine tumours: the role of imaging for diagnosis and therapy |
| Q38378364 | Nuclear imaging of neuroendocrine tumors with unknown primary: why, when and how? |
| Q53051729 | Radiolabeled probes targeting hypoxia-inducible factor-1-active tumor microenvironments. |
| Q38233342 | Role of (18) F-FDOPA PET/CT imaging in endocrinology |
| Q91210565 | Role of biomarker tests for diagnosis of neuroendocrine tumours |
| Q38966288 | Role of positron emission tomography imaging in Multiple Endocrine Neoplasia syndromes |
| Q89584441 | SPECT/CT Imaging of Mycobacterium tuberculosis Infection with [125I]anti-C3d mAb |
| Q55020340 | The Place of PET to Assess New Therapeutic Effectiveness in Neurodegenerative Diseases. |
| Q48110909 | The adrenal medulla and extra-adrenal paraganglia: then and now. |
| Q42427772 | Urology pertinent neuroendocrine tumors: focusing on renal pelvis, bladder, prostate located sympathetic functional paragangliomas. |
| Q57640099 | Vertebral metastases from neuroendocrine tumours: How to avoid false positives on Ga-DOTA-TOC PET using CT pattern analysis? |
Search more.